SULT1D1P: A Potential Drug Target and Biomarker (G133150)

Target Name: SULT1D1P

NCBI ID: G133150

SULT1D1P

Other Name(s): SULT1D1 | Sulfotransferase family, cytosolic, 1D, member 1, pseudogene | sulfotransferase family 1D member 1, pseudogene

SULT1D1P: A Potential Drug Target and Biomarker

Sulfasalazine, also known as sult1d1p, is a drug that is currently being investigated as a potential treatment for various diseases, including inflammatory disorders, autoimmune diseases, and gastrointestinal diseases. Sulfasalazine is an oral small molecule inhibitor of the enzyme Sodium-Glucose Transporter 1 (SGT1), which is responsible for transporting glucose across the cell membrane. In this article, we will discuss the potential mechanisms of sulfasalazine as a drug target and biomarker, as well as its current status in clinical trials.

Mechanisms of Sulfasalazine as a Drug Target

Sulfasalazine is an inhibitor of SGT1, which is an enzyme that is involved in the transport of glucose across the cell membrane. This means that when SGT1 is blocked, glucose is unable to enter the cell, which can lead to a decrease in the level of glucose in the cell. Sulfasalazine works by binding to the active site of SGT1 and inhibiting its catalytic activity. This inhibition of SGT1 allows the body to better regulate the level of glucose in the cell, which can have a variety of therapeutic effects.

Sulfasalazine has been shown to have a wide range of potential therapeutic effects, including the treatment of inflammatory disorders, autoimmune diseases, and gastrointestinal diseases. For example, in clinical trials, sulfasalazine has been shown to be effective in treating ulcerative colitis, a common inflammatory bowel disease, and in reducing the symptoms of inflammatory bowel disease.

Mechanisms of Sulfasalazine as a Biomarker

Sulfasalazine has also been shown to be a potential biomarker for several diseases, including inflammatory disorders and gastrointestinal diseases. For example, in clinical trials, researchers have found that levels of sulfasalazine in the stool can be used as a biomarker for the treatment of inflammatory bowel disease. Additionally, sulfasalazine has been shown to be able to distinguish between individuals with and without inflammatory bowel disease, which can further aid in the diagnosis and treatment of this disease.

Current Status of Sulfasalazine in Clinical Trials

Sulfasalazine is currently being investigated as a potential drug target and biomarker in a variety of clinical trials. For example, several studies are underway to investigate the potential efficacy and safety of sulfasalazine in treating inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Additionally, researchers are studying the potential mechanisms of sulfasalazine in treating these diseases, including its ability to modulate the activity of SGT1 and other genes involved in inflammation.

Conclusion

Sulfasalazine is an oral small molecule inhibitor of the enzyme SGT1, which is involved in the transport of glucose across the cell membrane. In clinical trials, sulfasalazine has been shown to have a wide range of potential therapeutic effects, including the treatment of inflammatory disorders and gastrointestinal diseases. Additionally, sulfasalazine has also been shown to be a potential biomarker for several diseases, including inflammatory bowel disease. With further research, sulfasalazine has the potential to be a valuable tool in the treatment of a variety of diseases.

Protein Name: Sulfotransferase Family 1D Member 1, Pseudogene

The "SULT1D1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SULT1D1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets